The historical rank and industry rank for Valerio Therapeutics's OCF Margin % or its related term are showing as below:
XPAR:ALVIO'
s OCF Margin % Range Over the Past 10 Years
Min: -966.22 Med: -280.47 Max: 71.47
Current: 71.47
During the past 13 years, the highest OCF Margin % of Valerio Therapeutics was 71.47%. The lowest was -966.22%. And the median was -280.47%.
XPAR:ALVIO's OCF Margin % is ranked better than 97.9% of 951
companies
in the Biotechnology industry
Industry Median: -64.23
vs XPAR:ALVIO: 71.47
Valerio Therapeutics OCF Margin % Related Terms
Valerio Therapeutics OCF Margin % Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVIO vs VRTX, REGN, ALNY: OCF Margin % Comparison
For the Biotechnology subindustry, Valerio Therapeutics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (XPAR:ALVIO) has a OCF Margin % of 222.35% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Valerio Therapeutics and its competitors. According to the industry distribution chart, Valerio Therapeutics ranks #20 out of 951 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Valerio Therapeutics' OCF Margin % too high?
Valerio Therapeutics' current OCF Margin % is 222.35%. Based on the distribution chart, Valerio Therapeutics ranks #20 out of 951 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #20 out of 951 companies for OCF Margin %. This places Valerio Therapeutics in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current OCF Margin % is 222.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.51 — trading 628.6% above its estimated fair value. The current OCF Margin % is 222.35%. Valerio Therapeutics' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current OCF Margin % is 222.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.51 is trading 628.6% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for XPAR:ALVIO:
OCF Margin %: 222.35%
GF Value™: €0.07 vs. price of €0.51 (628.6% above fair value)
No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score
Get the complete analysis for XPAR:ALVIO
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVIO has been successfully added to your 
